Incorporation of obidoxime into human serum albumin nanoparticles: Optimisation of preparation parameters for the development of a stable formulation

Journal of Microencapsulation

Volumn 27, Issue 7, 2010, Pages 594-601

  Kufleitner, Jürgen ^a   Worek, Franz ^b   Kreuter, Jörg ^a  

^a GOETHE UNIVERSITY   (Germany)

^b BUNDESWEHR INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (Germany)

Author keywords

Drug delivery; Human serum albumin; Incorporation; Nanoparticles; Obidoxime

Indexed keywords

ALBUMIN; ALCOHOL; OBIDOXIME;

ALBUMIN BLOOD LEVEL; ARTICLE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CROSS LINKING; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG RELEASE; DRUG SYNTHESIS; DRUG TRANSPORT; HUMAN; IN VITRO STUDY; PH;

CHEMISTRY, PHARMACEUTICAL; CROSS-LINKING REAGENTS; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; DRUG STABILITY; ETHANOL; HUMANS; HYDROGEN-ION CONCENTRATION; NANOPARTICLES; OBIDOXIME CHLORIDE; SERUM ALBUMIN; TEMPERATURE; TIME FACTORS;

EID: 77957795791     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652048.2010.501395     Document Type: Article

References (23)

1. Damascelli B, Cantu G, Mattavelli F, Tamplenizza P, Bidoli P, Leo E, Dosio F, Cerrotta AM, Di Tolla G, Frigerio LF, et al. Intraarterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorpo-rated in albumin nanoparticles (ABI-007): Phase I study ofpatients with squamous cell carcinoma of the head and neck and anal canal: Preliminary evidence ofclinical activity. Cancer, 2001;92:2592-602.
2. Dreis S, Rothweiler F, Michaelis M, Cinatl Jr J, Kreuter J, Langer K. Preparation, characterisation and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles. Int J Pharm, 2007;341:207-14.
3. Eyer P. The role of oximes in the management of organophosphorus pes-ticide poisoning. Toxicol Rev, 2003;22:165-90.
4. Eyer P, Worek F, 2007. Oximes. In: Marrs TC, Maynard RL, and Sidell FR, eds. Chemical Warfare Agents. 2nd ed. Chichester: Wiley & Sons. pp. 305-29.
5. Gunnell D, Eddleston M. Suicide by intentional ingestion of pesticides: A continuing tragedy in developing countries. Int J Epidemiol, 2003;32:902-9.
6. Kiderlen D, Worek F, Klimmek R, Eyer P. The phosphoryl oxime-destroying activity of human plasma. Arch Toxicol, 2000;74:27-32.
7. Kreuter J, Hekmatara T, Dreis S, Vogel T, Gelperina S, Langer K. Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain. J Control Release, 2007;118:54-8.
8. Kufleitner J, Wagner S, Worek F, von Briesen H, Kreuter J. Adsorption of obidoxime onto human serum albumin nanoparticles: Loading capacity, particle size and drug release. J Microencapsul, 2010;27:506-13.
9. Langer K, Anhorn MG, Steinhauser I, Dreis S, Celebi D, Schrickel N, Faust S, Vogel V. Human serum albumin (HSA) nanoparticles: Reproducibility of preparation process and kinetics of enzymatic deg-radation. Int J Pharm, 2008;347:109-17.
10. Langer K, Balthasar S, Vogel V, Dinauer N, von Briesen H, Schubert D. Optimization of the preparation process for human serum albumin (HSA) nanoparticles. Int J Pharm, 2003;257:169-80.
11. Leo E, Brina B, Forni F, Vandelli MA. In vitro evaluation of PLA nanoparticles containing a lipophilic drug in water-soluble or insoluble form. Int J Pharm, 2004;278:133-41.
12. Lundy PM, Shih TM. Examination of the role of central cholinergic mechanisms in the therapeutic effects ofHI-6 in organophosphate poisoning. J Neurochem, 1983;40:1321-8.
13. Michaelis K, Hoffmann MM, Dreis S, Herbert E, Alyautdin RN, Michaelis M, Kreuter J, Langer K. Covalent linkage of apolipoprotein e to albumin nanoparticles strongly enhances drug transport into the brain. J Pharmacol Exp Ther, 2006;317:1246-53.
14. Paudyal BP. Organophosphorous poisoning. J Nepal Med Assoc, 2008;47:251-8.
15. Pignatello R, Bucolo C, Spedalieri G, Maltese A, Puglisi G. Flurbiprofenloaded acrylate polymer nanosuspensions for ophthalmic application. Biomaterials, 2002;23:3247-55.
16. Rubnov S, Shats I, Levy D, Amisar S, Schneider H. Autocatalytic degradation and stability of obidoxime. J Pharm Pharmacol, 1999;51:9-14.
17. Spöhrer U, Eyer P. Separation of geometrical syn and anti isomers of obidoxime by ion-pair high-performance liquid chromatography. J Chromatogr A, 1995;693:55-61.
18. Steinhauser I, Spankuch B, Strebhardt K, Langer K. Trastuzumab-modified nanoparticles: Optimisation of preparation and uptake in cancer cells. Biomaterials, 2006;27:4975-83.
19. Ulbrich K, Hekmatara T, Herbert E, Kreuter J. Transferrin-and trans-ferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur J Pharm Biopharm, 2009;71:251-6.
20. Wartlick H, Michaelis K, Balthasar S, Strebhardt K, Kreuter J, Langer K. Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells. J Drug Target, 2004;12:461-71.
21. Weber C, Kreuter J, Langer K. Desolvation process and surface character-istics ofHSA-nanoparticles. Int J Pharm, 2000;196:197-200.
22. Worek F, Widmann R, Knopff O, Szinicz L. Reactivating potency of obidoxime, pralidoxime, HI 6 and HLo 7 in human erythrocyte acetyl- cholinesterase inhibited by highly toxic organophosphorus compounds. Arch Toxicol, 1998;72:237-43.
23. Zensi A, Begley D, Pontikis C, Legros C, Mihoreanu L, Wagner S, Buchel C, von Briesen H, Kreuter J. Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. J Control Release, 2009;137:78-86.